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Introduction
Folic acid and derivatives (folates) are required by mam-
malian cells to carry out one-carbon transfer reactions 
and the de novo synthesis of nucleic acids [1]. Folate 
cannot be synthesized de novo and must be consumed. 
Once internalized, folic acid is reduced by dihydrofolate 
reductase (DHFR) to tetrahydrofolate, which then can 
act to deliver one carbon units to acceptor molecules. 
Antifolates target rapidly cycling cancer cells, whose 
enhanced need of one carbon units for de novo pyrimi-
dine and purine synthesis leaves them vulnerable to 
DHFR inhibition [2]. Aminopterin, a DHFR inhibitor, 
was the first antifolate used in the clinic, but it fell out 
of favor when less toxic methotrexate (MTX) was intro-
duced in the 1950s [3]. MTX continues to be included in 
many therapeutic regimens today.
Pralatrexate (PDX) is a second generation antifolate 
recently approved for the treatment of peripheral T-cell 
lymphoma [4]. In addition to inhibiting DHFR, PDX also 
is an excellent substrate for folylpolyglutamate synthase 
(FPGS) which polyglutamylates folates, leading to greater 
cellular retention and activity, and the reduced folate car-
rier-1 (RFC-1), the primary folate membrane transporter 
[5]. These additional PDX properties that increase PDX 
transport and retention in cancer cells lead to improved 
efficacy when compared to MTX [6].
Adverse events associated with antifolates can be 
severe, commonly mucositis and leukopenia. A strategy to 
avoid toxicity and still provide clinical benefit is the inclu-
sion of leucovorin (LV) in high-dose MTX regimens [7]. 
LV is a stable, reduced form of folate that is converted to 
tetrahydrofolate without requiring DHFR, thus bypassing 
the inhibition of tetrahydrofolate synthesis by MTX and 
PDX. LV also competes for binding with antifolates at the 
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reduced folate carrier, and when converted to tetrahydro-
folate, competes with antifolates for polyglutamylation 
(Fig. 1).
In this study, we demonstrate the protective effect of 
LV on PDX toxicity and show that a significant antitumor 




Five thousand H2052 pleural mesothelioma cells per well 
were plated in 96-well plates in RPMI 1640 media (Gibco) 
supplemented with 10 % dialyzed FBS (Invitrogen). The 
following day, spent media was removed and fresh media 
containing drug was added and plates were incubated for 
24 h. Drug containing media was removed and media con-
taining 2μM LV was added and plates were incubated for 
24 h. LV containing media was removed and fresh media 
was added to the plates incubated for 48 h. The Cell Titer 
96 Aqueous One Solution (Promega) assay was used to 
assess cell viability at the end of the experiment according 
to manufacturers’ protocol. Data were analyzed using the 
GraphPad Prism 6 software package (GraphPad Software 
Inc.).
In vivo experiments
Eight- to 10-week-old female nude mice (Taconic) 
were subcutaneously injected on the right flank with 
5 million H2052 cells in a 1:1 mixture of matrigel (BD 
Biosciences) and PBS (Gibco). Mice were monitored 
until palpable tumors developed and reached a size of 
100 mm3. Mice were then randomized and split into 
the following treatment groups: saline control; 60 or 
180 mg/kg PDX on days 1, 4 and 7; 60 or 180 mg/kg 
PDX on days 1, 4 and 7 followed by 50 mg/kg LV 24, 
32 and 48 h after each PDX administration; 50 mg/kg 
LV following the above schedule. General toxicity was 
monitored through weight loss. Tumor dimensions were 
measured every 2–4 days using calipers, and tumor vol-
ume was calculated using the following equation: Vol-
ume = (width2) × (length/2). All animal experiments 
were approved by the Rutgers Institutional Animal Care 
and Use Committee.
Results
To assess the sensitivity to antifolate therapy, a compari-
son of MTX, PDX and pemetrexed in the pleural meso-
thelioma cell line H2052 was performed. After a 24 h 
treatment with drug, the media was removed and replaced 
with fresh media and cultured a further 72 h. PDX dem-
onstrated significant efficacy over MTX in this assay, with 
IC50 values of 0.625 and 80 nM, respectively (Fig. 2a, b). 
The large difference between PDX and MTX is likely 
due to enhanced transport and retention of PDX. H2052 
cells were also more sensitive to PDX than pemetrexed 
(Fig. 2c), an antifolate currently used in the clinic to treat 
mesothelioma. 
As LV can abrogate antifolate toxicity, we next exam-
ined if efficacy of PDX would be compromised by the 
addition of LV 24 h later. H2052 cells were treated with 
antifolate as before, but media containing 2μM LV was 
added for another 24 h period, followed by removal of 
drugs and culture in fresh media for a further 48 h. The 
addition of 2μM LV raised the IC50 slightly for MTX 
and pemetrexed (Fig. 2d). The effect of LV on tumor 
cell sensitivity to PDX was only at high PDX concentra-
tions, and was not expected to be significant in in vivo 
xenografts. We predicted that using PDX in combination 
with LV rescue would result in an increased therapeutic 
index.
The effect of LV treatment on PDX efficacy and toxic-
ity was examined using H2052 xenografts in nude mice 
(Fig. 3). Using 60 mg/kg as the equivalent clinical dose, 
tumor regression was seen both with and without LV treat-
ment in this cohort. Efficacy was nearly identical, but mice 
that were treated with LV had less toxicity and bodyweight 
remained close to control animals.
To mimic high-dose MTX treatment with LV rescue, 
using PDX, we included a cohort treated at 180 mg/kg 
Fig. 1  Leucovorin (LV) may abrogate pralatrexate (PDX) activity 
through three mechanisms. i Competition for reduced folate carrier 
type 1 (RFC) transport into cell. ii Competition for polyglutamyla-
tion, a retention and activity marker, by folylpolyglutamate synthase 
(FPGS). iii Provides an alternate source of tetrahydrofolate, working 
around PDX inhibition of dihydrofolate reductase (DHFR)
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PDX with and without LV rescue. Without LV rescue, 
mice lost a large amount of weight, had poor BCS scores 
and had to be killed according to institutional protocol 
(Fig. 3b). Mice rescued with LV exhibited some weight 
loss, and a durable response lasting several weeks was 
observed (Fig. 3a).
Discussion
Surgical resection followed by chemotherapy is the pre-
ferred method of treatment for malignant mesothelioma 
[9]. The antifolate pemetrexed is currently used alone and 
in combination with cisplatin in treating mesothelioma, 
with modest response rates seen in the clinic [10]. Chemo-
therapy is primarily palliative in mesothelioma and there is 
a need for new and innovative therapies that have the abil-
ity to improve patient outcomes [11].
There were no responses to PDX in a phase II study 
in mesothelioma [12]. To improve tolerability, PDX was 
administered at 135 mg/m3 biweekly instead of weekly, 
possibly limiting clinical effectiveness. A dose schedule of 
PDX weekly with LV rescue may demonstrate improved 
antitumor activity with tolerable toxicity. Supporting this 
conclusion, a small recent case series exploring LV res-
cue and PDX in T-cell cutaneous lymphoma found that LV 
rescue allowed patients to tolerate PDX therapy while pre-
serving efficacy [8]. Dose scheduling must be optimized in 
patients, as the interval between antifolate and LV admin-
istration has recently been shown to be significant in deter-
mining the efficacy of therapy in vitro [13].
The incorporation of LV rescue with current PDX dos-
ing regimens may prove an effective method to prevent 
DLTs and increase the therapeutic index. While a phase II 
study of PDX in patients with mesothelioma did not show 
responses, higher doses with the inclusion of LV rescue 
Fig. 2  Pralatrexate (PDX) is more potent than methotrexate and 
pemetrexed in vitro. Dose response curves shown as percent of viable 
H2052 mesothelioma cells remaining after 24 h treatment with prala-
trexate (a), methotrexate (b) or pemetrexed (c) followed by 72 h cul-
ture in fresh media (solid line) or followed by 24 h culture in 2μM 
leucovorin and 48 h culture in media (dashed line). d A summary 
table of IC50 values
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into new and existing PDX treatment protocols should be 
explored as a way to expand the tolerability and effective-
ness of PDX in the clinic.
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